Table A.4.

Sensitivity analyses for vaccine eagerness in the full sample

Vaccine Eagerness	Analysis A (n = 1340)		Analysis B (n = 1174)		Analysis C (n = 1403)		Analysis D (n = 1111)
	Coef.	95% CI	Coef.	95% CI	Coef.	95% CI	Coef.	95% CI
Disease
Respiratory disease	ref		ref		ref		ref
Cancer	0.34	[-0.05,0.73]	0.33	[-0.04,0.70]	0.34	[-0.04,0.72]	0.33	[-0.04,0.69]
Genital warts	−0.14	[-0.44,0.15]	−0.11	[-0.37,0.14]	−0.14	[-0.44,0.15]	−0.11	[-0.35,0.12]
Safety
No side effect	ref		ref		ref		ref
Scientific surveillance	−0.20	[-0.50,0.09]	−0.30	[-0.63,0.03]	−0.23	[-0.52,0.06]	−0.28	[-0.62,0.07]
Safety other countries	−2.18***	[-2.41,-1.94]	−2.30***	[-2.59,-2.01]	−2.11***	[-2.35,-1.87]	−2.39***	[-2.68,-2.11]
Benefit/risk	−2.29***	[-2.77,-1.81]	−2.30***	[-2.71,-1.89]	−2.22***	[-2.69,-1.76]	−2.39***	[-2.82,-1.95]
Indirect Protection
Protects only you	ref		ref		ref		ref
Protects other people	0.38***	[0.23,0.54]	0.32***	[0.17,0.46]	0.37***	[0.22,0.53]	0.33***	[0.19,0.47]
Elimination	0.50***	[0.24,0.75]	0.52***	[0.35,0.69]	0.49***	[0.25,0.73]	0.53***	[0.34,0.71]
Coverage
Not enough	ref		ref		ref		ref
Already a third	0.72***	[0.34,1.11]	0.74***	[0.33,1.15]	0.71***	[0.32,1.10]	0.76***	[0.36,1.15]
Most adolescents	1.25***	[0.91,1.59]	1.33***	[0.94,1.72]	1.21***	[0.89,1.54]	1.38***	[0.97,1.79]
Other countries 80%	1.16***	[0.84,1.49]	1.17***	[0.81,1.53]	1.14***	[0.8,1.47]	1.20***	[0.85,1.55]

A: excluding participants with invariant certainty; B: excluding participants with low response time; C: excluding participants with both invariant certainty and low response time; D: excluding participants with at least one characteristic. *: p-value<0.05; **: p-value<0.01; ***: p-value<0.001.